Drug Profile
Benzonatate polacrilex
Latest Information Update: 28 Oct 2018
Price :
$50
*
At a glance
- Originator Alitair Pharmaceuticals Inc
- Class Aminobenzoic acids; Antitussives
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Cough
Highest Development Phases
- No development reported Cough
Most Recent Events
- 28 Oct 2018 No recent reports of development identified for research development in Cough in USA (PO)
- 16 Sep 2014 Benzonatate polacrilex is available for licensing as of 16 Sep 2014. http://www.alitair.com/
- 16 Sep 2014 Early research in Cough in USA (PO)